Much remains unknown about diseases and the way our bodies respond to them, in part because the human genome is the complete DNA assembly that makes each person unique.
A Virginia Tech professor and his team of researchers have created a new epigenomic technology to help understand how the human body battles diseases that could lead to precision medicine based on epigenomic features of an individual patient.
In a recently published article in Nature Protocols, Chang Lu, the Fred W. Bull Professor of Chemical Engineering at Virginia Tech, along with chemical engineering doctoral students Bohan Zhu and Yuan-Pang Hsieh, describe a microfluidic technology they are using to study a variety of diseases ranging from breast and brain cancer to schizophrenia and addiction.
Epigenomic technology
Lu said: “We were motivated by the fact that the molecular basis of a lot of diseases remains to be elusive after years of research, due to lack of advanced and precise technologies.”
The epigenomic technology developed includes detailed instructions for device fabrication, setup, and operation of microfluidic oscillatory washing-based chromatin immunoprecipitation followed by a sequencing method called MOWChIP-seq, a low-input technology that allows characterisation of the epigenome using as few as 100 cells.
The method is novel because up until now, conventional methods required tens of millions of cells per assay. But by using the new sequencing method, the team has discovered they can produce a profile of histone modifications using as few as 100 cells per assay with a throughput as high as eight assays in one run.
“By comparing normal and diseased epigenomes, useful markers and patterns can be discovered and used for precision medicine based on epigenomic features of an individual patient,” Lu said.
This research builds upon Lu’s previous work in developing the MOWChIP-seq, first published in a Nature Methods paper in 2015. A US patent was awarded to Lu and his former doctoral student, Zhenning Cao, for their work. Compared to their original 2015 publication, in the current protocol Lu and his team detailed their recent effort on automating the MOWChIP-seq process and processing eight samples in parallel in one run.
The team’s process is semi-automated and reduces labour and improves reproducibility and is scalable.
Lu’s research is supported by the National Cancer Institute, the National Institute of Biomedical Imaging and Bioengineering, the National Human Genome Research Institute of the National Institutes of Health, and the Virginia Tech Institute for Critical Technology and Applied Science’s Center for Engineered Health.
